HomePRQR • NASDAQ
ProQR Therapeutics NV
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 4.74M | 1.74% |
Operating expense | 15.56M | 22.16% |
Net income | -10.08M | -31.61% |
Net profit margin | -212.59 | -29.37% |
Earnings per share | -0.11 | -10.72% |
EBITDA | -10.14M | -37.30% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 132.41M | 28.92% |
Total assets | 151.69M | 22.45% |
Total liabilities | 72.75M | -18.30% |
Total equity | 78.94M | — |
Shares outstanding | 105.34M | — |
Price to book | 2.41 | — |
Return on assets | -16.92% | — |
Return on capital | -26.83% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -10.08M | -31.61% |
Cash from operations | -15.80M | -4.40% |
Cash from investing | -224.00K | 98.74% |
Cash from financing | -500.00K | -19.33% |
Net change in cash | -16.99M | 48.83% |
Free cash flow | -11.93M | -10.91% |
Previous close
$1.81
Day range
$1.75 - $1.83
Year range
$1.08 - $4.62
Market cap
186.23M USD
Avg Volume
490.12K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer. Wikipedia
Founded
2012
Website
Employees
166
